Endometrial glandular dysplasia and endometrial intraepithelial neoplasia

Xiaofang Yi, Wenxin - Zheng

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: In recent decades, progress has been made in defining endometrial precancers. Endometrial intraepithelial neoplasia has been widely accepted as a precancer of type I endometrial cancer, while endometrial glandular dysplasia is a newly described entity as a probable precancer of type II cancer. As endometrial intraepithelial neoplasia has been discussed more extensively in the literature, we focus more on the recent development of endometrial glandular dysplasia in this review. RECENT FINDINGS: Serous endometrial intraepithelial carcinoma was previously considered as a putative precancer for endometrial serous carcinoma or uterine papillary serous carcinoma. It is now considered as an early form of endometrial serous carcinoma, however. Endometrial glandular dysplasia was found to be a better candidate for precancer for both endometrial serous and clear cell carcinomas, which meets almost all recently defined criteria for precancer. Biomarkers of p53 and IMP3 are helpful for the early detection of endometrial glandular dysplasia as well as type II endometrial cancers. SUMMARY: Two types of endometrial cancers are derived from two different precancers. Type I endometrioid carcinoma develops from endometrial intraepithelial neoplasia, while type II derives most probably from endometrial glandular dysplasia. Recognition and correct detection of endometrial glandular dysplasia may deepen our understanding and improve prevention and clinical management for type II endometrial cancer.

Original languageEnglish (US)
Pages (from-to)20-25
Number of pages6
JournalCurrent Opinion in Obstetrics and Gynecology
Volume20
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Endometrial Neoplasms
Neoplasms
Endometrioid Carcinoma
Papillary Carcinoma
Carcinoma in Situ
Biomarkers
Carcinoma

Keywords

  • Endometrial carcinoma
  • Endometrial glandular dysplasia
  • Endometrial intraepithelial neoplasia
  • Precancer of endometrial carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Endometrial glandular dysplasia and endometrial intraepithelial neoplasia. / Yi, Xiaofang; Zheng, Wenxin -.

In: Current Opinion in Obstetrics and Gynecology, Vol. 20, No. 1, 02.2008, p. 20-25.

Research output: Contribution to journalArticle

@article{eaabe0af5e6047978f23648f5dc6f75f,
title = "Endometrial glandular dysplasia and endometrial intraepithelial neoplasia",
abstract = "PURPOSE OF REVIEW: In recent decades, progress has been made in defining endometrial precancers. Endometrial intraepithelial neoplasia has been widely accepted as a precancer of type I endometrial cancer, while endometrial glandular dysplasia is a newly described entity as a probable precancer of type II cancer. As endometrial intraepithelial neoplasia has been discussed more extensively in the literature, we focus more on the recent development of endometrial glandular dysplasia in this review. RECENT FINDINGS: Serous endometrial intraepithelial carcinoma was previously considered as a putative precancer for endometrial serous carcinoma or uterine papillary serous carcinoma. It is now considered as an early form of endometrial serous carcinoma, however. Endometrial glandular dysplasia was found to be a better candidate for precancer for both endometrial serous and clear cell carcinomas, which meets almost all recently defined criteria for precancer. Biomarkers of p53 and IMP3 are helpful for the early detection of endometrial glandular dysplasia as well as type II endometrial cancers. SUMMARY: Two types of endometrial cancers are derived from two different precancers. Type I endometrioid carcinoma develops from endometrial intraepithelial neoplasia, while type II derives most probably from endometrial glandular dysplasia. Recognition and correct detection of endometrial glandular dysplasia may deepen our understanding and improve prevention and clinical management for type II endometrial cancer.",
keywords = "Endometrial carcinoma, Endometrial glandular dysplasia, Endometrial intraepithelial neoplasia, Precancer of endometrial carcinoma",
author = "Xiaofang Yi and Zheng, {Wenxin -}",
year = "2008",
month = "2",
doi = "10.1097/GCO.0b013e3282f2fd50",
language = "English (US)",
volume = "20",
pages = "20--25",
journal = "Current Opinion in Obstetrics and Gynecology",
issn = "1040-872X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Endometrial glandular dysplasia and endometrial intraepithelial neoplasia

AU - Yi, Xiaofang

AU - Zheng, Wenxin -

PY - 2008/2

Y1 - 2008/2

N2 - PURPOSE OF REVIEW: In recent decades, progress has been made in defining endometrial precancers. Endometrial intraepithelial neoplasia has been widely accepted as a precancer of type I endometrial cancer, while endometrial glandular dysplasia is a newly described entity as a probable precancer of type II cancer. As endometrial intraepithelial neoplasia has been discussed more extensively in the literature, we focus more on the recent development of endometrial glandular dysplasia in this review. RECENT FINDINGS: Serous endometrial intraepithelial carcinoma was previously considered as a putative precancer for endometrial serous carcinoma or uterine papillary serous carcinoma. It is now considered as an early form of endometrial serous carcinoma, however. Endometrial glandular dysplasia was found to be a better candidate for precancer for both endometrial serous and clear cell carcinomas, which meets almost all recently defined criteria for precancer. Biomarkers of p53 and IMP3 are helpful for the early detection of endometrial glandular dysplasia as well as type II endometrial cancers. SUMMARY: Two types of endometrial cancers are derived from two different precancers. Type I endometrioid carcinoma develops from endometrial intraepithelial neoplasia, while type II derives most probably from endometrial glandular dysplasia. Recognition and correct detection of endometrial glandular dysplasia may deepen our understanding and improve prevention and clinical management for type II endometrial cancer.

AB - PURPOSE OF REVIEW: In recent decades, progress has been made in defining endometrial precancers. Endometrial intraepithelial neoplasia has been widely accepted as a precancer of type I endometrial cancer, while endometrial glandular dysplasia is a newly described entity as a probable precancer of type II cancer. As endometrial intraepithelial neoplasia has been discussed more extensively in the literature, we focus more on the recent development of endometrial glandular dysplasia in this review. RECENT FINDINGS: Serous endometrial intraepithelial carcinoma was previously considered as a putative precancer for endometrial serous carcinoma or uterine papillary serous carcinoma. It is now considered as an early form of endometrial serous carcinoma, however. Endometrial glandular dysplasia was found to be a better candidate for precancer for both endometrial serous and clear cell carcinomas, which meets almost all recently defined criteria for precancer. Biomarkers of p53 and IMP3 are helpful for the early detection of endometrial glandular dysplasia as well as type II endometrial cancers. SUMMARY: Two types of endometrial cancers are derived from two different precancers. Type I endometrioid carcinoma develops from endometrial intraepithelial neoplasia, while type II derives most probably from endometrial glandular dysplasia. Recognition and correct detection of endometrial glandular dysplasia may deepen our understanding and improve prevention and clinical management for type II endometrial cancer.

KW - Endometrial carcinoma

KW - Endometrial glandular dysplasia

KW - Endometrial intraepithelial neoplasia

KW - Precancer of endometrial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=38149025011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38149025011&partnerID=8YFLogxK

U2 - 10.1097/GCO.0b013e3282f2fd50

DO - 10.1097/GCO.0b013e3282f2fd50

M3 - Article

VL - 20

SP - 20

EP - 25

JO - Current Opinion in Obstetrics and Gynecology

JF - Current Opinion in Obstetrics and Gynecology

SN - 1040-872X

IS - 1

ER -